vs
辉瑞（PFE）与TIGO ENERGY, INC.（TYGO）财务数据对比。点击上方公司名可切换其他公司
辉瑞的季度营收约是TIGO ENERGY, INC.的1.9倍（$17.6B vs $9.2B），辉瑞自由现金流更多（$4.5B vs $-39.3M）
辉瑞是总部位于美国纽约曼哈顿The Spiral的跨国制药及生物技术企业，由德国企业家查尔斯·辉瑞与查尔斯·F·埃尔哈特于1849年在纽约创立，是北美地区历史最悠久的制药企业之一，在全球医药健康领域拥有较高的行业影响力。
Tigo Energy是一家美国企业，总部位于加利福尼亚州洛斯加托斯，专注服务光伏领域的安装商、经销商与原始设备制造商，主打产品与技术包括组件级功率优化器及智能组件功率电子器件，同时也为行业客户提供配套软件与相关服务。
PFE vs TYGO — 直观对比
营收规模更大
PFE
是对方的1.9倍
$9.2B
自由现金流更多
PFE
多$4.5B
$-39.3M
损益表 — Q4 FY2025 vs Q4 FY2023
| 指标 | | |
|---|---|---|
| 营收 | $17.6B | $9.2B |
| 净利润 | $-1.6B | — |
| 毛利率 | 70.0% | 0.0% |
| 营业利润率 | -9.4% | — |
| 净利率 | -9.4% | — |
| 营收同比 | -1.2% | — |
| 净利润同比 | -501.7% | -1736.1% |
| 每股收益（稀释后） | $-0.29 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PFETYGO
| Q4 25 | $17.6B | — | ||
| Q3 25 | $16.7B | — | ||
| Q2 25 | $14.7B | — | ||
| Q1 25 | $13.7B | — | ||
| Q4 24 | $17.8B | — | ||
| Q3 24 | $17.7B | — | ||
| Q2 24 | $13.3B | — | ||
| Q1 24 | $14.9B | — |
净利润PFETYGO
| Q4 25 | $-1.6B | — | ||
| Q3 25 | $3.5B | — | ||
| Q2 25 | $2.9B | — | ||
| Q1 25 | $3.0B | — | ||
| Q4 24 | $410.0M | — | ||
| Q3 24 | $4.5B | — | ||
| Q2 24 | $41.0M | — | ||
| Q1 24 | $3.1B | — |
毛利率PFETYGO
| Q4 25 | 70.0% | — | ||
| Q3 25 | 74.9% | — | ||
| Q2 25 | 74.2% | — | ||
| Q1 25 | 79.3% | — | ||
| Q4 24 | 66.7% | — | ||
| Q3 24 | 70.3% | — | ||
| Q2 24 | 75.2% | — | ||
| Q1 24 | 77.3% | — |
营业利润率PFETYGO
| Q4 25 | -9.4% | — | ||
| Q3 25 | 20.0% | — | ||
| Q2 25 | 20.8% | — | ||
| Q1 25 | 20.3% | — | ||
| Q4 24 | -0.1% | — | ||
| Q3 24 | 26.6% | — | ||
| Q2 24 | -0.8% | — | ||
| Q1 24 | 23.0% | — |
净利率PFETYGO
| Q4 25 | -9.4% | — | ||
| Q3 25 | 21.3% | — | ||
| Q2 25 | 19.9% | — | ||
| Q1 25 | 21.6% | — | ||
| Q4 24 | 2.3% | — | ||
| Q3 24 | 25.2% | — | ||
| Q2 24 | 0.3% | — | ||
| Q1 24 | 20.9% | — |
每股收益（稀释后）PFETYGO
| Q4 25 | $-0.29 | — | ||
| Q3 25 | $0.62 | — | ||
| Q2 25 | $0.51 | — | ||
| Q1 25 | $0.52 | — | ||
| Q4 24 | $0.07 | — | ||
| Q3 24 | $0.78 | — | ||
| Q2 24 | $0.01 | — | ||
| Q1 24 | $0.55 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.1B | $31.2M |
| 总债务越低越好 | — | $50.0M |
| 股东权益账面价值 | $86.5B | $62.8M |
| 总资产 | $208.2B | $127.8M |
| 负债/权益比越低杠杆越低 | — | 0.80× |
8季度趋势，按日历期对齐
现金及短期投资PFETYGO
| Q4 25 | $1.1B | — | ||
| Q3 25 | $1.3B | — | ||
| Q2 25 | $1.6B | — | ||
| Q1 25 | $1.4B | — | ||
| Q4 24 | $1.0B | — | ||
| Q3 24 | $1.1B | — | ||
| Q2 24 | $1.1B | — | ||
| Q1 24 | $719.0M | — |
股东权益PFETYGO
| Q4 25 | $86.5B | — | ||
| Q3 25 | $92.8B | — | ||
| Q2 25 | $88.7B | — | ||
| Q1 25 | $90.3B | — | ||
| Q4 24 | $88.2B | — | ||
| Q3 24 | $92.3B | — | ||
| Q2 24 | $87.7B | — | ||
| Q1 24 | $92.3B | — |
总资产PFETYGO
| Q4 25 | $208.2B | — | ||
| Q3 25 | $208.7B | — | ||
| Q2 25 | $206.1B | — | ||
| Q1 25 | $208.0B | — | ||
| Q4 24 | $213.4B | — | ||
| Q3 24 | $219.5B | — | ||
| Q2 24 | $216.2B | — | ||
| Q1 24 | $221.1B | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $5.3B | $-37.2M |
| 自由现金流经营现金流 - 资本支出 | $4.5B | $-39.3M |
| 自由现金流率自由现金流/营收 | 25.6% | -0.4% |
| 资本支出强度资本支出/营收 | 4.8% | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $9.1B | $-70.6M |
8季度趋势，按日历期对齐
经营现金流PFETYGO
| Q4 25 | $5.3B | — | ||
| Q3 25 | $4.6B | — | ||
| Q2 25 | $-582.0M | — | ||
| Q1 25 | $2.3B | — | ||
| Q4 24 | $6.7B | — | ||
| Q3 24 | $6.7B | — | ||
| Q2 24 | $-1.8B | — | ||
| Q1 24 | $1.1B | — |
自由现金流PFETYGO
| Q4 25 | $4.5B | — | ||
| Q3 25 | $4.0B | — | ||
| Q2 25 | $-1.2B | — | ||
| Q1 25 | $1.8B | — | ||
| Q4 24 | $5.8B | — | ||
| Q3 24 | $6.1B | — | ||
| Q2 24 | $-2.4B | — | ||
| Q1 24 | $386.0M | — |
自由现金流率PFETYGO
| Q4 25 | 25.6% | — | ||
| Q3 25 | 24.0% | — | ||
| Q2 25 | -8.2% | — | ||
| Q1 25 | 12.9% | — | ||
| Q4 24 | 32.7% | — | ||
| Q3 24 | 34.3% | — | ||
| Q2 24 | -18.2% | — | ||
| Q1 24 | 2.6% | — |
资本支出强度PFETYGO
| Q4 25 | 4.8% | — | ||
| Q3 25 | 3.6% | — | ||
| Q2 25 | 4.2% | — | ||
| Q1 25 | 4.1% | — | ||
| Q4 24 | 5.2% | — | ||
| Q3 24 | 3.7% | — | ||
| Q2 24 | 4.8% | — | ||
| Q1 24 | 4.7% | — |
现金转化率PFETYGO
| Q4 25 | — | — | ||
| Q3 25 | 1.30× | — | ||
| Q2 25 | -0.20× | — | ||
| Q1 25 | 0.79× | — | ||
| Q4 24 | 16.39× | — | ||
| Q3 24 | 1.50× | — | ||
| Q2 24 | -43.44× | — | ||
| Q1 24 | 0.35× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PFE
| U.S.Commercial Division | $9.0B | 51% |
| Specialty Care | $4.8B | 27% |
| Total Alliance Biopharmaceuticals | $2.6B | 15% |
| Royalty | $480.0M | 3% |
| Pfizer Centre One | $409.0M | 2% |
TYGO
暂无分部数据
